The estimated Net Worth of Allan Shaw is at least 6.59 千$ dollars as of 13 January 2017. Allan Shaw owns over 1,389 units of VIVUS stock worth over 6,590$ and over the last 9 years Allan sold VVUS stock worth over 0$.
Sign up
Allan Shaw VVUS stock SEC Form 4 insiders trading
Allan has made over 6 trades of the VIVUS stock since 2016, according to the Form 4 filled with the SEC. Most recently Allan exercised 1,389 units of VVUS stock worth 648$ on 13 January 2017.
The largest trade Allan's ever made was exercising 1,389 units of VIVUS stock on 13 January 2017 worth over 648$. On average, Allan trades about 189 units every 3 days since 2015. As of 13 January 2017 Allan still owns at least 14,126 units of VIVUS stock.
You can see the complete history of Allan Shaw stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Allan Shaw's mailing address?
Allan's mailing address filed with the SEC is C/O VIVUS, INC., 351 EAST EVELYN AVENUE, MOUNTAIN VIEW, CA, 94041.
Insiders trading at VIVUS
Over the last 21 years, insiders at VIVUS have traded over 6,261,269$ worth of VIVUS stock and bought 5,180,746 units worth 13,074,554$ . The most active insiders traders include Tide Capital, Llc North Tid...、Alexander J Denner、Ernest Mario. On average, VIVUS executives and independent directors trade stock every 39 days with the average trade being worth of 35,394$. The most recent stock trade was executed by John P. Amos on 1 March 2019, trading 11,000 units of VVUS stock currently worth 53,350$.
What does VIVUS do?
VIVUS, Inc. engages in the development and commercialization of novel therapeutic products. The firm's products are indicated for the treatment of obese and overweight patients, exocrine pancreatic insufficiency, and erectile dysfunction. Its products include PANCREAZE, Qsymia, and STENDRA/SPEDRA. The company was founded by Virgil A. Place in April 16, 1991 and is headquartered in Campbell, CA.
What does VIVUS's logo look like?
Complete history of Allan Shaw stock trades at Akari Therapeutics Plc、VIVUS
VIVUS executives and stock owners
VIVUS executives and other stock owners filed with the SEC include:
-
John Amos,
Chief Executive Officer, Director -
John Slebir,
Senior Vice President - Business Development, General Counsel, Secretary -
Santosh Varghese,
Senior Vice President, Chief Medical Officer -
Mark Oki,
Chief Financial Officer, Senior Vice President, Chief Accounting Officer -
Thomas King,
Independent Director -
David Norton,
Independent Chairman of the Board -
Jill Frizzley,
Independent Director -
Herman Rosenman,
Independent Director -
Jorge Plutzky,
Independent Director -
Edward Kangas,
Independent Director -
Karen Ferrell,
Independent Director -
Allan Shaw,
Director -
Herm Rosenman,
Director -
Eric W Roberts,
Director -
Tide Capital, Llc North Tid...,
-
Seth H. Z. Fischer,
Chief Executive Officer -
Mayu Sris,
Director -
Kenneth Suh,
President -
Wesley Day,
Vice President, Clinical -
Michael /Ny/ Miller,
Chief Commercial Officer -
Wang Changjin,
VP, Business Development -
Virgil A Place,
Chairman & CSO -
Graham Strachan,
Director -
Samuel F Colin,
Director -
Ernest Mario,
Director -
Anthony P. Zook,
Chief Executive Officer -
John W Dietrich,
Vice President, R & D -
Terry Nida,
VP, Worldwide Marketing/ -
Svai S Sanford,
Interim CFO -
Mario M Rosati,
Director -
Alexander J Denner,
Director -
Jon C Biro,
10% owner -
J Martin Carroll,
Director -
Robert N Wilson,
Director -
Alexander J Sarissa Capital...,
-
M. Scott Oehrlein,
Chief Operations Officer -
Timothy E Morris,
VP, Finance and CFO -
Leland F Wilson,
President & CEO -
Linda M Dairiki Shortliffe,
Director -
Charles J Casamento,
Director -
Lee Perry,
Vice President & Chief -
Jacob Pieter Kastelein Joha...,
Director -
Michael J Astrue,
Director -
Mark B Logan,
Director -
Michael Patrick Miller,
SVP, Chief Commercial Officer -
Guy P Marsh,
VP, Operations & General Mgr. -
Neil Gesundheit,
VP, Chief Medical Officer -
Larry J Strauss,
Vice President, Finance & CFO -
James R Nickel,
Vice President, Clinical -
Peter Y Tam,
VP, Business Planning -
Carol Zoltowski,
Vice President, Regulatory -
Lori Forrest,
VP, Operations & General Mgr.